Keenova Therapeutics plc reports company news around its branded therapeutics portfolio for rare and unaddressed conditions. Recurring updates cover financial results, clinical publications, disease-awareness campaigns, and presentations involving products and programs such as Acthar Gel, XIAFLEX, TERLIVAZ, and collagenase clostridium histolyticum research.
The company's communications emphasize specialty therapeutic areas that include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. News also covers integration activity following its business combination, U.S. manufacturing operations, and portfolio performance drivers across established branded medicines.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.